Galectin Therapeutics Inc. Reports Positive Additional Results from NAVIGATE TrialOn February 18, 2025, Galectin Therapeutics Inc. (NASDAQ: GALT) announced significant findings from the NAVIGATE trial regarding belapectin, its therapeutic focus on ta
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Galectin Therapeutics’s 8K filing here. Galectin Therapeutics Company Profile (Get Free Report) Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and […]
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Galectin Therapeutics’s 8K filing here. Galectin Therapeutics Company Profile (Get Free Report) Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and […]
